SCM
TNGX icon

Suvretta Capital Management’s Tango Therapeutics TNGX Stock Holding History

Suvretta Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,662,227
Closed -$23.6M – 107
2025
Q4 		$23.6M Buy
+2,662,227
New +$22.9M 0.48% 53
2021
Q1 		– Sell
-100,000
Closed -$1.14M – 129
2020
Q4 		$1.14M Hold
100,000
– – 0.02% 96
2020
Q3 		$1.04M Buy
+100,000
New +$1.02M 0.02% 86

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Suvretta Capital Management's TNGX Position: Q1 2026 in Review

Suvretta Capital Management sold out of Tango Therapeutics (TNGX) in Q1 2026, closing a stake of 2,662,227 shares — an estimated $23.6M sold.

Suvretta Capital Management first reported a position in TNGX in Q3 2020 and held it in 3 quarters. The position peaked at $23.6M in Q4 2025. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Suvretta Capital Management reported no remaining Tango Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Suvretta Capital Management sold 2,662,227 Tango Therapeutics shares in Q1 2026, an estimated $23.6M.
  • Suvretta Capital Management first reported a position in Tango Therapeutics in Q3 2020 and held it in 3 quarters.
  • Suvretta Capital Management's Tango Therapeutics position peaked at $23.6M in Q4 2025.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Suvretta Capital Management's 13F filing for Q1 2026, filed 15 May 2026.